Corporate Update on Quoin Pharmaceuticals Ltd. (Ticker: QNRX)
Quoin Pharmaceuticals Ltd. (QNRX) recorded a 1.24 % decline in its share price during the 24‑hour trading window that closed at 11:43 PM Central Europe on Thursday, 22 October 2026. At the time of reporting, a single share of Quoin Lt traded for approximately USD 4.01 on the Nasdaq. The company’s outstanding shares total 4.8 million, giving it a market capitalization of USD 19.4 million. In the past 24 hours, the total volume of Quoin Lt shares exchanged on public markets amounted to roughly USD 31.1 k.
Historical Performance
- Year‑to‑Date Trend: Since the close of last month, Quoin Lt shares have fallen by 43.08 %.
- 200‑Day Simple Moving Average: The average price over the last 200 trading days sits at USD 6.34.
- 52‑Week Range: The highest price reached during the most recent 52‑week period was USD 23.50 on 25 November 2025, while the lowest point was USD 3.25 on 23 June 2026.
Comparative Market Activity
The performance of a selection of peers over the same 24‑hour period highlights a range of sector dynamics:
| Company | Ticker | 24‑Hour Change | Current Price | Market Capitalization | P/E Ratio |
|---|---|---|---|---|---|
| Lifeward | LFWD | -1.96 % | USD 5.82 | USD 15.9 m | – |
| RocketDNA | RKT.AX | -4.17 % | AUD 0.02 | AUD 32.1 m | – |
| Partner Communications | PTNR.TA | +3.18 % | ILA 3,700 | ILA 2.3 bn | 22.21 |
| Delta Galil | DELG.TA | +2.29 % | ILA 18,240 | ILA 1.6 bn | 15.74 |
| Mind Cti | MNDO | -1.10 % | USD 0.91 | USD 18.5 m | 5.56 |
RocketDNA’s Recent Corporate Actions
RocketDNA announced on 21 October 2026 that it will issue two million options at an exercise price of three cents. Vesting will occur after one year, contingent on continued engagement with the firm, and the options will expire after four years. The aim is to align the interests of board members with those of shareholders as the company expands its autonomous drone and geospatial data services. In a related move, the company appointed Chris Crosby—a mining technical leader with extensive expertise in surveying, mine planning, and spatial technology—to its Advisory Board. Crosby will receive a comparable option grant, reinforcing RocketDNA’s strategy to integrate advanced mining technologies into its platform.
Company Focus
Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic products for rare and orphan diseases. Operating globally, the company maintains a strong focus on delivering innovative solutions to underserved patient populations. Its corporate website, www.quoinpharma.com , provides detailed information about its product pipeline, research initiatives, and corporate governance.
This article presents an objective summary of recent market activity and corporate developments related to Quoin Pharmaceuticals Ltd. and its peer group, aiming to provide stakeholders with a clear and concise overview of the company’s current standing within the broader market context.
